Sirolimus (Rapamycin)

A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.

Also Known As:

Networked: 7416 relevant articles (578 outcomes, 1223 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Serruys, Patrick W: 64 articles (02/2015 - 06/2002)
2.	Kwiatkowski, David J: 38 articles (12/2015 - 10/2002)
3.	Leon, Martin B: 38 articles (03/2015 - 10/2003)
4.	Kastrati, Adnan: 30 articles (08/2015 - 08/2004)
5.	Blagosklonny, Mikhail V: 28 articles (04/2015 - 09/2006)
6.	Moses, Jeffrey W: 28 articles (01/2010 - 10/2003)
7.	Schömig, Albert: 27 articles (11/2013 - 04/2004)
8.	Valgimigli, Marco: 26 articles (06/2015 - 05/2004)
9.	Park, Seung-Jung: 24 articles (05/2015 - 02/2005)
10.	Campistol, Josep M: 24 articles (09/2014 - 01/2004)

Related Diseases

1.	Neoplasms (Cancer) 04/01/2009 - "Rapamycin inhibition of cell proliferation, the cell cycle and mTOR signaling, including p70S6 and S6RP phosphorylation, was most effective in benign (MCF10A) and premalignant (MCF10AT; MCF10ATG3B) human breast epithelial cells, relative to MCF10CA1a tumor cells. " 01/22/2008 - "Tumor cell proliferation (measured by Ki-67 staining) was dramatically reduced in seven of 14 patients after 1 wk of rapamycin treatment and was associated with the magnitude of mTOR inhibition (p = 0.0047, Fisher exact test) but not the intratumoral rapamycin concentration. " 06/01/2010 - "Collectively, we conclude that mTORC2 plays a much more important role than mTORC1 in rapamycin-mediated phosphorylation of Akt and ERK, and cotargeting AKT and ERK signaling may be a new strategy for enhancing the efficacy of rapamycin-based therapeutic approaches in cancer cells." 06/01/1983 - "A new drug (rapamycin) being investigated by the NCI was found to be very effective against the U-251 tumor. " 10/13/2015 - "Mice harboring subcutaneous gallbladder tumors, treated with WYE-354 or rapamycin, exhibited a significant reduction in tumor mass. "
2.	Renal Cell Carcinoma (Grawitz Tumor) 04/01/2014 - "Inhibitors of the mammalian target of rapamycin (mTOR) have improved the treatment of renal cell carcinoma (RCC). " 01/01/2010 - "This sirolimus derivative has shown clinical efficacy in monotherapy for poor-risk renal cell carcinoma leading to an overall survival of 10.8 months in the pivotal phase III trial of this agent. " 12/01/2009 - "Clinical trials have validated the importance of mammalian target of rapamycin (mTOR) as a therapeutic target in patients with advanced renal cell carcinoma (RCC). " 08/15/2009 - "Clinical trials have validated the importance of mammalian target of rapamycin (mTOR) as a targeted mechanism in the treatment of renal cell carcinoma (RCC). " 08/01/2008 - "In a randomised controlled trial of advanced renal cell carcinoma patients, targeted therapy to mTOR by means of rapamycin analogues has been shown to significantly improve survival. "
3.	Myocardial Infarction 12/01/2012 - "We propose that rapamycin is a novel and clinically relevant pharmacological strategy to target STAT3 activation for treatment of myocardial infarction." 09/01/2008 - "However, the incidence of myocardial infarct may be, slightly but significantly, reduced with sirolimus DES. " 05/15/2007 - "(Sirolimus Eluting Stenting in Acute Myocardial Infarction; http://www.clinicaltrials.gov/ct/show/NCT00288210; NCT00288210)." 01/01/1995 - "Focal myocardial infarction was observed in three of five rats with Rapamycin given at 1.5 mg/kg/day and two of 22 rats with 1.0 mg/kg/day. " 03/08/2007 - "There was a significant reduction in the combined risk of death, myocardial infarction, or reintervention (hazard ratio, 0.43; 95% CI, 0.34 to 0.54) associated with the use of sirolimus-eluting stents. "
4.	Hyperplasia 04/01/2011 - "The NEVO SES with focal release of sirolimus from reservoirs achieved significantly greater and more consistent suppression of neointimal hyperplasia than the surface-coated TAXUS Liberté PES. " 06/01/2003 - "Neointimal hyperplasia is refractory to conventional immunosuppression although newer agents, such as rapamycin, have shown considerable promise in controlling it. " 08/01/2010 - "In either case, mice lacking Gab2 or treated with rapamycin showed attenuated myeloid hyperplasia and modestly improved survival, but the effects were not cytotoxic and were reversible. " 06/01/2005 - "To evaluate the efficacy of limited short-term systemic administration of rapamycin to prevent neointimal intimal hyperplasia (NIH) in a double-injury rat model of restenosis. " 05/10/2012 - "A perivascular system releasing sirolimus prevented intimal hyperplasia in a rabbit model in a medium-term study."
5.	Tuberous Sclerosis (Bourneville's Disease) 07/01/2015 - "Clinical and Histologic Analysis of the Efficacy of Topical Rapamycin Therapy Against Hypomelanotic Macules in Tuberous Sclerosis Complex." 07/01/2015 - "Efficacy of Rapamycin in Tuberous Sclerosis-Associated Hypopigmented Macules: Back to the Future." 09/01/2012 - "Topical rapamycin therapy to alleviate the cutaneous manifestations of tuberous sclerosis complex: a double-blind, randomized, controlled trial to evaluate the safety and efficacy of topically applied rapamycin." 05/21/2008 - "Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function." 03/01/2005 - "Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models."

Related Drugs and Biologics

1.	everolimus
2.	Calcineurin
3.	Sirolimus (Rapamycin)
4.	Paclitaxel (Taxol)
5.	temsirolimus
6.	Phosphotransferases (Kinase)
7.	Cyclosporine (Ciclosporin)
8.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
9.	Tacrolimus (Prograf)
10.	Polymers

Related Therapies and Procedures

1.	Stents
2.	Transplants (Transplant)
3.	Transplantation (Transplant Recipients)
4.	Heterologous Transplantation (Xenotransplantation)
5.	Homologous Transplantation (Allograft)